BioCentury
ARTICLE | Clinical News

NGM reports Phase II data for NGM282 in primary sclerosing cholangitis

April 27, 2018 7:49 PM UTC

NGM Biopharmaceuticals Inc. (South San Francisco, Calif.) reported additional data from a Phase II trial in 62 primary sclerosing cholangitis (PSC) patients with elevated alkaline phosphatase levels showing that once-daily subcutaneous 3 mg NGM282 significantly reduced serum alanine aminotransferase (ALT) levels by 40 U/L and serum aspartate aminotransferase (AST) levels by 23 U/L from baseline to week 12 vs. placebo (p<0.01 for both). The once-daily 1 and 3 mg doses of NGM282 both significantly reduced bile acid synthesis and total bile acid levels from baseline to week 12 vs. placebo. Data were presented at the European Association for the Study of the Liver (EASL) meeting in Paris.

In February, the company reported top-line data from the double-blind, international trial showing that both doses of NGM282 missed the primary endpoint of reducing serum alkaline phosphatase levels from baseline to week 12 vs. placebo...